5.48
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
15.36%
85.81
|
74.38 | 71.54 | 60.12 | 60.10 |
|
|
2.05%
69.03
|
67.65 | 67.06 | 63.21 | 58.42 |
| Benefits Costs and Expenses |
291.29
|
- | - | - | 260.17 |
| Costs And Expenses |
38.03%
93.38
|
67.65 | 67.06 | 63.21 | 81.88 |
| Operating Income/Loss |
149.19%
16.77
|
6.731 | 4.482 | -3.09 | 1.679 |
| Income/Loss From Continuing Operations Before Tax |
376.26%
-205.48
|
74.38 | -1.928 | -9.22 | -200.07 |
| Income Tax Expense/Benefit, Deferred |
-
|
- | - | - | - |
| Income Tax Expense/Benefit |
-
|
- | - | - | - |
| Income/Loss From Continuing Operations After Tax |
1,684%
11.08
|
0.621 | -1.928 | -9.22 | -5.113 |
|
|
1,684%
11.08
|
0.621 | -1.928 | -9.22 | -5.113 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
98.86%
1.8657
|
163.65 | 159.46 | 152.45 | 0.8106 |
| Diluted Average Shares |
92.01%
14.18
|
177.62 | 159.46 | 152.45 | 0.8106 |
| Basic Earnings Per Share |
0.07
|
- | -0.01 | -0.06 | -0.03 |
| Diluted Earnings Per Share |
0.07
|
- | -0.01 | -0.06 | -0.03 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):